Table 2.

Exogenous compounds (n=93) fortified in blank urine at 1000µg/L to investigate interferences and fortified into a low JWH-018 N-(5-hydroxypentyl) cutoff (5µg/L) to investigate potential signal suppression.

2C-B	diazepam	nicotine
11-OH-THC	diphenhydramine	nitrazepam
6-acetylcodeine	ecgonine	norbenzoylecgonine
6-acetylmorphine	ecgonine ethyl ester	norbuprenorphine
7-aminoclonazepam	ecgonine methyl ester	norcocaethylene
7-aminoflunitrazepam	EDDP	norcocaine
7-aminonitrazepam	EMDP	norcodeine
acetaminophen	ephedrine	norcotinine
acetylsalicylic acid	ethylamphetamine	nordiazepam
alprazolam	flunitrazepam	norfluoxetine
amphetamine	fluoxetine	normorphine
anhydroecgonine methyl ester	flurazepam	noroxycodone
BDB	HMA	noroxymorphone
benzoylecgonine	HMMA	oxazepam
bromazepam	hydrocodone	oxycodone
brompheniramine	hydromorphine	oxymorphone
buprenorphine	ibuprofen	paroxetine
caffeine	imipramine	pentazocine
cannabigerol	ketamine	phentermine
cannabidiol	lorazepam	p-hydroxyamphetamine
cannabinol	MBDB	p-hydroxybenzoylecgonine
cathinone	MDA	p-hydroxycocaine
chlorpheniramine	MDEA	p-hydroxymethamphetamine
clomipramine	MDMA	p-methoxyamphetamine
clonazepam	methadone	p-methoxymethamphetamine
clonidine	methaphetamine	propoxyphene
cocaethylene	m-hydroxybenzoylecgonine	pseudoephedrine
cocaine	m-hydroxycocaine	temazepam
codeine	morphine	THC
cotinine	morphine-3-glucuronide	THCCOOH
dextromethorphan	morphine-6-glucuronide	trans-3’-hydroxycotinine

2C-B: 4-bromo-2,5-dimethoxyphenethylamine

11-OH-THC: 11-hydroxy-Δ9-tetrahydrocannabinol

BDB: 3,4-(methylenedioxyphenyl)-2-butanamine

EDDP: 2-ethylidene-1,5-dimethyl-3-3-diphenylpyrrolidine

EMDP: 2-ethylidene-5-methyl-3-3-diphenylpyraline

HMA: 4-hydroxy-3-methoxyamphetamine

HMMA: 4-hydroxy-3-methoxymethamphetamine

MBDB: n-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine

MDA: 3,4-methylenedioxyamphetamine

MDEA: 3,4- methylenedioxyethylamphetamine

MDMA: 3,4-methylenedioxymethamphetamine

THC: Δ9-tetrahydrocannabinol

THCCOOH: 11-nor-9-carboxy-Δ9-tetrahydrocannabinol